News
SNY
47.71
+0.44%
0.21
Why Cytokinetics Stock Was a Nearly 5% Winner Today
The Motley Fool · 1d ago
Sanofi to buy China rights to Cytokinetics lead asset
Seeking Alpha · 1d ago
Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS
TipRanks · 1d ago
Sanofi to acquire rights to develop, commercialize aficamten from Corxel
TipRanks · 1d ago
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
Barchart · 1d ago
Cytokinetics Announces Sanofi's Acquisition Of Aficamten Rights For HCM Treatment In Greater China
Benzinga · 1d ago
Sanofi To Buy Rights To Develop Cytokinetics' Aficamten In Greater China From Corxel
NASDAQ · 1d ago
CYTOKINETICS INC - ELIGIBLE FOR UP TO $150 MILLION IN MILESTONE PAYMENTS FROM SANOFI
Reuters · 1d ago
CYTOKINETICS: SANOFI WILL ACQUIRE CORXEL'S RIGHTS RELATING TO AFICAMTEN IN GREATER CHINA FOR UNDISCLOSED AMOUNT
Reuters · 1d ago
Regeneron reports positive results for two anti-coagulant drugs
Seeking Alpha · 2d ago
PRESSE RELEASE: JEAN-PAUL KRESS TO JOIN SANOFI'S BOARD OF DIRECTORS
Reuters · 2d ago
California Gov. Newsom declares State of Emergency over bird flu
Seeking Alpha · 3d ago
CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts
Benzinga · 3d ago
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Benzinga · 3d ago
CDC Confirms First Severe Case Of H5N1 Bird Flu In U.S. On December 13; Patient Hospitalized With Severe Case Of Avian Influenza A Virus Infection In Louisiana
Benzinga · 3d ago
Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?
NASDAQ · 3d ago
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance
Barchart · 3d ago
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Barchart · 3d ago
Promising Potential: Sanofi’s Strong Pipeline and Strategic Market Focus Drive Buy Rating
TipRanks · 3d ago
TD says Spyre has ‘superior TL1A program’ after Teva data
TipRanks · 4d ago
More
Webull provides a variety of real-time SNY stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.